437 related articles for article (PubMed ID: 28338503)
21. Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Schuehly U; Ayalasomayajula S; Buchbjerg J; Pal P; Golor G; Prescott MF; Sunkara G; Hinder M; Langenickel TH
Eur J Clin Pharmacol; 2018 Sep; 74(9):1121-1130. PubMed ID: 29974143
[TBL] [Abstract][Full Text] [Related]
22. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
24. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.
Almarjan AI; Almarjan SA; Masoud AT
High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
26. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials.
Geng Q; Yan R; Wang Z; Hou F
Cardiology; 2020; 145(9):589-598. PubMed ID: 32726791
[TBL] [Abstract][Full Text] [Related]
27. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
28. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
30. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Shaddy R; Canter C; Halnon N; Kochilas L; Rossano J; Bonnet D; Bush C; Zhao Z; Kantor P; Burch M; Chen F
Am Heart J; 2017 Nov; 193():23-34. PubMed ID: 29129252
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
Rerick L; Elston C; Kester J; Montepara C; Gengler B
J Cardiovasc Pharmacol; 2021 Mar; 77(3):343-348. PubMed ID: 33298737
[TBL] [Abstract][Full Text] [Related]
35. Sacubitril/valsartan (Entresto) for heart failure.
Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
[No Abstract] [Full Text] [Related]
36. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
Han Y; Zhou Y; Na J; Li F; Sun Y
Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Sacubitril/Valsartan in Hypertension.
Malik AH; Aronow WS
Am J Ther; 2022 May-Jun 01; 29(3):e322-e333. PubMed ID: 30664018
[TBL] [Abstract][Full Text] [Related]
40. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
